-
Je něco špatně v tomto záznamu ?
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium
D. Poulimeneas, M. Koniordou, D. Kousi, C. Merakou, I. Kopsidas, GC. Tsopela, CD. Argyropoulos, SC. Themistocleous, G. Shiamakkides, M. Constantinou, A. Alexandrou, E. Noula, A. Nearchou, J. Salmanton-García, FA. Stewart, S. Heringer, K. Albus,...
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
101037867
European Union's Horizon 2020 Research and Innovation Programme
NLK
Directory of Open Access Journals
od 2013
Free Medical Journals
od 2013
PubMed Central
od 2013
Europe PubMed Central
od 2013
ProQuest Central
od 2013-03-01
Open Access Digital Library
od 2013-01-01
Open Access Digital Library
od 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
PubMed
38140188
DOI
10.3390/vaccines11121784
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within-and across-countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.
Centro Hospitalar Universitário do Porto 4099 001 Porto Portugal
Centro Nacional de Microbiología Instituto de Salud Carlos 3 28220 Madrid Spain
Collaborative Center for Clinical Epidemiology and Outcomes Research 15451 Athens Greece
Czech Clinical Research Infrastructure Network 62500 Brno Czech Republic
Department of Clinical Pharmacology Medical University Vienna 1090 Vienna Austria
Department of Infectious Diseases Karolinska University Hospital 17177 Stockholm Sweden
Department of Medicine Division of Infectious Diseases Karolinska Institutet 17177 Stockholm Sweden
Department of Pharmacology Faculty of Medicine Masaryk University 60177 Brno Czech Republic
European Vaccine Initiative 69115 Heidelberg Germany
German Centre for Infection Research Partner Site Bonn Cologne 38124 Cologne Germany
Hospital La Paz Institute for Health Research 28046 Madrid Spain
Influenza Centre Department of Clinical Science University of Bergen 5020 Bergen Norway
Institute of Clinical Medicine Medical Faculty Vilnius University 03101 Vilnius Lithuania
Ministry of Health of Israel Jerusalem 1176 Israel
National Koranyi Institute for Pulmonology 1121 Budapest Hungary
School of Medicine European University Cyprus Nicosia 2404 Cyprus
Servicio Madrileño de Salud 28046 Madrid Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23022429
- 003
- CZ-PrNML
- 005
- 20240206144020.0
- 007
- ta
- 008
- 240105s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/vaccines11121784 $2 doi
- 035 __
- $a (PubMed)38140188
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Poulimeneas, Dimitrios $u Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), 15451 Athens, Greece
- 245 14
- $a The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium / $c D. Poulimeneas, M. Koniordou, D. Kousi, C. Merakou, I. Kopsidas, GC. Tsopela, CD. Argyropoulos, SC. Themistocleous, G. Shiamakkides, M. Constantinou, A. Alexandrou, E. Noula, A. Nearchou, J. Salmanton-García, FA. Stewart, S. Heringer, K. Albus, E. Álvarez-Barco, A. Macken, R. Di Marzo, C. Luis, P. Valle-Simón, HH. Askling, M. Hellemans, O. Spivak, RJ. Davis, AM. Azzini, I. Barta, L. Součková, L. Jancoriene, M. Akova, PWG. Mallon, OF. Olesen, J. Frias-Iniesta, P. van Damme, K. Tóth, M. Cohen-Kandli, RJ. Cox, P. Husa, P. Nauclér, L. Marques, J. Ochando, E. Tacconelli, M. Zeitlinger, OA. Cornely, ZD. Pana, TE. Zaoutis, VACCELERATE Consortium
- 520 9_
- $a Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within-and across-countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Koniordou, Markela $u Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), 15451 Athens, Greece $1 https://orcid.org/0000000260341291
- 700 1_
- $a Kousi, Dimitra $u Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), 15451 Athens, Greece
- 700 1_
- $a Merakou, Christina $u Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), 15451 Athens, Greece $1 https://orcid.org/000000022098599X
- 700 1_
- $a Kopsidas, Ioannis $u Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), 15451 Athens, Greece $1 https://orcid.org/0000000164994807
- 700 1_
- $a Tsopela, Grammatiki Christina $u Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), 15451 Athens, Greece
- 700 1_
- $a Argyropoulos, Christos D $u School of Medicine, European University Cyprus, Nicosia 2404, Cyprus $1 https://orcid.org/0000000220902162
- 700 1_
- $a Themistocleous, Sophia C $u School of Medicine, European University Cyprus, Nicosia 2404, Cyprus
- 700 1_
- $a Shiamakkides, George $u School of Medicine, European University Cyprus, Nicosia 2404, Cyprus
- 700 1_
- $a Constantinou, Marinos $u School of Medicine, European University Cyprus, Nicosia 2404, Cyprus
- 700 1_
- $a Alexandrou, Alexandra $u School of Medicine, European University Cyprus, Nicosia 2404, Cyprus
- 700 1_
- $a Noula, Evgenia $u School of Medicine, European University Cyprus, Nicosia 2404, Cyprus
- 700 1_
- $a Nearchou, Andria $u School of Medicine, European University Cyprus, Nicosia 2404, Cyprus
- 700 1_
- $a Salmanton-García, Jon $u Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Institute of Translational Research, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $u German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 38124 Cologne, Germany $u Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $1 https://orcid.org/0000000267668297
- 700 1_
- $a Stewart, Fiona A $u Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Institute of Translational Research, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $u German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 38124 Cologne, Germany $1 https://orcid.org/0000000210295768
- 700 1_
- $a Heringer, Sarah $u Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Institute of Translational Research, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $u German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 38124 Cologne, Germany $u Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $1 https://orcid.org/0000000176800344
- 700 1_
- $a Albus, Kerstin $u Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Institute of Translational Research, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $u Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $1 https://orcid.org/0000000311244310
- 700 1_
- $a Álvarez-Barco, Elena $u Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland
- 700 1_
- $a Macken, Alan $u Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland $1 https://orcid.org/0000000333208767
- 700 1_
- $a Di Marzo, Romina $u European Vaccine Initiative (EVI), 69115 Heidelberg, Germany $1 https://orcid.org/0000000287150348
- 700 1_
- $a Luis, Catarina $u European Vaccine Initiative (EVI), 69115 Heidelberg, Germany
- 700 1_
- $a Valle-Simón, Paula $u Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain $u Servicio Madrileño de Salud, 28046 Madrid, Spain
- 700 1_
- $a Askling, Helena H $u Department of Infectious Diseases, Karolinska University Hospital, 17177 Stockholm, Sweden $u Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, 17177 Stockholm, Sweden
- 700 1_
- $a Hellemans, Margot $u VAXINFECTIO, Centre of Evaluation of Vaccination, Faculty of Medicine and Health Science, Universiteit Antwerpen, 2610 Antwerp, Belgium $1 https://orcid.org/0009000529261559
- 700 1_
- $a Spivak, Orly $u Ministry of Health of Israel, Jerusalem 1176, Israel
- 700 1_
- $a Davis, Ruth Joanna $u Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy
- 700 1_
- $a Azzini, Anna Maria $u Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy $1 https://orcid.org/0000000271482559
- 700 1_
- $a Barta, Imre $u National Koranyi Institute for Pulmonology, 1121 Budapest, Hungary $1 https://orcid.org/0000000300675166
- 700 1_
- $a Součková, Lenka $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 60177 Brno, Czech Republic $u University Hospital Brno, 62500 Brno, Czech Republic $u Czech Clinical Research Infrastructure Network (CZECRIN), 62500 Brno, Czech Republic $7 xx0204153
- 700 1_
- $a Jancoriene, Ligita $u Institute of Clinical Medicine, Medical Faculty, Vilnius University, 03101 Vilnius, Lithuania $u Vilnius University Hospital Santaros Klinikos, Medical Faculty, Vilnius University, 03101 Vilnius, Lithuania $1 https://orcid.org/0000000164886312
- 700 1_
- $a Akova, Murat $u Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Haceteppe University, Ankara 06230, Turkey $1 https://orcid.org/0000000269049473 $7 xx0197408
- 700 1_
- $a Mallon, Patrick W G $u Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland
- 700 1_
- $a Olesen, Ole F $u European Vaccine Initiative (EVI), 69115 Heidelberg, Germany $1 https://orcid.org/0000000230252466
- 700 1_
- $a Frias-Iniesta, Jesus $u Hospital La Paz Institute for Health Research (IdiPAZ), 28046 Madrid, Spain $u Servicio Madrileño de Salud, 28046 Madrid, Spain
- 700 1_
- $a van Damme, Pierre $u VAXINFECTIO, Centre of Evaluation of Vaccination, Faculty of Medicine and Health Science, Universiteit Antwerpen, 2610 Antwerp, Belgium
- 700 1_
- $a Tóth, Krisztina $u National Koranyi Institute for Pulmonology, 1121 Budapest, Hungary
- 700 1_
- $a Cohen-Kandli, Miriam $u Ministry of Health of Israel, Jerusalem 1176, Israel
- 700 1_
- $a Cox, Rebecca Jane $u Influenza Centre, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway $1 https://orcid.org/0000000283414078
- 700 1_
- $a Husa, Petr $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 60177 Brno, Czech Republic $u University Hospital Brno, 62500 Brno, Czech Republic $u Czech Clinical Research Infrastructure Network (CZECRIN), 62500 Brno, Czech Republic $1 https://orcid.org/0000000291902610
- 700 1_
- $a Nauclér, Pontus $u Department of Infectious Diseases, Karolinska University Hospital, 17177 Stockholm, Sweden $u Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, 17177 Stockholm, Sweden
- 700 1_
- $a Marques, Laura $u Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugal
- 700 1_
- $a Ochando, Jordi $u Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Madrid, Spain
- 700 1_
- $a Tacconelli, Evelina $u Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, 37134 Verona, Italy
- 700 1_
- $a Zeitlinger, Markus $u Department of Clinical Pharmacology, Medical University Vienna, 1090 Vienna, Austria
- 700 1_
- $a Cornely, Oliver A $u Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Institute of Translational Research, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $u German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 38124 Cologne, Germany $u Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $u Clinical Trials Centre Cologne (ZKS Köln), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany $u Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany $1 https://orcid.org/0000000195993137
- 700 1_
- $a Pana, Zoi Dorothea $u School of Medicine, European University Cyprus, Nicosia 2404, Cyprus
- 700 1_
- $a Zaoutis, Theoklis E $u Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), 15451 Athens, Greece $u 2nd Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
- 710 2_
- $a VACCELERATE Consortium
- 773 0_
- $w MED00200686 $t Vaccines $x 2076-393X $g Roč. 11, č. 12 (2023)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38140188 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240105 $b ABA008
- 991 __
- $a 20240206144017 $b ABA008
- 999 __
- $a ok $b bmc $g 2036286 $s 1208874
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 11 $c 12 $e 20231129 $i 2076-393X $m Vaccines $n Vaccines (Basel) $x MED00200686
- GRA __
- $a 101037867 $p European Union's Horizon 2020 Research and Innovation Programme
- LZP __
- $a Pubmed-20240105
